&w=3840&q=100)
Wells Fargo suspends China travel after employee exit ban: Report
Reuters
Wells Fargo has suspended all travel to China after a banker was blocked from leaving the country, a person familiar with the matter told Reuters on Thursday.
The US banking giant's Chenyue Mao was subjected to an exit ban after she entered China in recent weeks, the Wall Street Journal reported, citing people familiar with the matter.
"We are closely tracking this situation and working through the appropriate channels so our employee can return to the United States as soon as possible," Wells Fargo said in a statement emailed to Reuters.
The ban could worsen concerns among multinational companies about the risks of doing business in China, particularly around employee safety and freedom of movement. The incident could also chill corporate travel to the country and complicate relations between the world's two biggest economies.
Broader US-China relations remain tense, shaped by deepening strategic, economic, and geopolitical rivalries.
Mao was born in Shanghai and is based in Atlanta, according to a June 2025 release from FCI, where she serves as chairwoman. FCI, formerly named Factors Chain International, is a global network of companies that do business in the factoring and financing of trade receivables.
Before her election as FCI chair in June, Mao served as vice chair of the body. The industry body did not immediately respond to a Reuters request for comment on the matter.
Mao is a US citizen, the source said.
She has been a banker at Wells Fargo for over a decade, according to her LinkedIn profile. She currently serves as a managing director at the lender and spearheads its international factoring business, as well as advising multinational clients on cross-border working-capital strategies.
Factoring is a financing method where companies sell their receivables to third parties, such as banks, in exchange for immediate cash. The third party, known as the factor, profits by purchasing the receivables at a discount and collecting the full amount later.
The Wall Street Journal reported that it could not be determined precisely when Mao entered China, or what prompted the travel restriction.
She has worked and interacted with Chinese companies and industry groups on trade financing and international factoring matters, the Journal reported, adding that she also sometimes traveled to China for business.
Beijing has increasingly used exit bans on both Chinese and foreign nationals, often in connection with civil disputes, regulatory investigations or criminal probes.
Many affected individuals are unaware of the restrictions until they attempt to leave the country.
Mao did not immediately respond to a Reuters request for comment on LinkedIn. The White House and China's foreign ministry did not immediately respond to requests for comment.
In September 2023, authorities in China ordered a senior Nomura banker overseeing the firm's investment banking operations there not to leave the mainland.
Some companies have canceled or delayed trips to China in recent years, while others have introduced safeguards such as advising staff to enter the country in groups rather than alone.
Human-rights group says, China is using exit bans more frequently, often targeting individuals under investigation or those asked to cooperate with government inquiries.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
41 minutes ago
- Time of India
Password for China Electronics Entry? Tech Transfer JVs
The government is likely to support Chinese investments in the electronics sector if they come through joint ventures with Indian firms and entail technology transfer, instead of only setting up assembly units, said officials. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The government is likely to support Chinese investments in the electronics sector if they come through joint ventures with Indian firms and entail technology transfer , instead of only setting up assembly units, said ministry of electronics and IT (MeitY) is clear that approval to some Chinese investments is critical for manufacturing to shift to India, as well as for the success of the upcoming component incentive scheme, they told ministry is, hence, backing easing of norms for investments from the neighbouring country, they views are aligned with those of the industry, which has been seeking government agreement for tie-ups with Chinese players, as well as those of government think tank Niti Aayog, which proposed allowing Chinese entities to buy up to 24% stake in Indian firms without additional backing for Chinese investments in electronics manufacturing comes close on the heels of external affairs minister S Jaishankar's meeting with his Chinese counterpart Wang Yi in officials, however, emphasised that Chinese investments should be permitted only in joint ventures with Indian partners and only if there is clarity on the way technology and know-how would be transferred.'If some player just wants to add assembly lines in partnership with a Chinese firm, it won't be supported,' an official privy to the details said, on condition of official said domestic players need to learn technology processes, and that if they have to scale up, Chinese support is needed. This is because many of the components and other manufacturers come from from China are also key to increasing local value addition in electronics products, a stated aim of the value addition in electronics has crossed 20% within six to seven years, with a major thrust coming from the production linked incentives scheme. The government has set a target of crossing 30% in the next two to three years and reaching 38% within five years. China has a local value addition of 38%, the highest in any country.A third official said MeitY will abide by the broader stance of the government, but has fundamentally been supportive of joint ventures where there's been technology industry executive pointed out that most of the cases that were cleared earlier through Press Note 3 – under which prior government approval is mandatory for investments from countries sharing a land border with India – were from MeitY because of the requirements of the domestic electronics sector.'What is fundamentally important for the government is that an electronics ecosystem needs to develop in India and if some joint venture proposals enable this, then support will be provided,' said a senior electronics executive, who did not wish to be companies have been pushing for a review of trade ties with China, particularly concerning Press Note 3. The Department for Promotion of Industry and Internal Trade, in 2020, tightened the foreign direct investment policy through Press Note 3 in the backdrop of the India-China border clashes earlier that local manufacturing of smartphones and their exports increasing sharply since 2020 at the cost of China, the latter has hit back with informal trade barriers since last year. Over the past eight months, it has extended the curbs to electronics adding to the woes of the domestic industry, China's latest restrictions on exports of rare earth materials spell potential input shortages for smartphone makers in India. China recently asked some of its companies to shutter their Indian operations and withdraw trained Indian personnel, in an effort to restrict technology is seeking to deepen and expand the supply chain by launching a Rs 22,919-crore electronics component manufacturing scheme to incentivise local push this, Indian companies need expertise from Chinese entities that currently make the bulk of the components supplied globally. Quite a few Indian contract manufacturers, such as Dixon Technologies and Bhagwati (Micromax), have signed joint venture agreements with Chinese partners that are awaiting approval from the electronics industry recently raised alarm over informal trade restrictions by China, saying they could dent its competitiveness and threaten the $32-billion smartphone exports target for this financial year.'These disruptions are leading to operational inefficiencies, impacting scale and above all raising costs of production, since producing this equipment locally or in collaboration with Japan or Korea costs three to four times more than Chinese imports,' the industry said in a recent letter to the government, seeking help to resolve the matter at the 2020, smartphone manufacturing in India has surged, with production of devices worth $64 billion in FY25, of which exports accounted for over $24 billion. In contrast, domestic mobile phone production was worth $26 billion in the 167th rank in India's exports basket in FY15, smartphones have climbed to become the country's principal export.
Time of India
42 minutes ago
- Time of India
Brookfield, EQT Close In on Gland Pharma, but Rising Stock a Pain
Live Events Buyout groups Brookfield and EQT are in active discussions to buy Hyderabad-based Gland Pharma, a contract development and manufacturing organisation (CDMO) and injectables company, from China's Fosun Group in what could become one of the largest buyouts of the year in the segment, said people in the know. However, the galloping share price of Gland is a potential deal two private equity groups have been shortlisted after the initial round of bids earlier this such as CVC Capital Partners are also exploring a deal, said the people cited. Warburg Pincus is said to be weighing its options before taking a call, they Chinese parent has diversified investments that range from healthcare to football clubs, asset management, banks, estate, hospitality, fashion and industrials. The conglomerate has a presence across the pharma value chain from manufacturing to diagnostics and medical devices. Shanghai Fosun Pharmaceutical Co. had acquired an 86% stake in Gland Pharma in 2016 from KKR for a record deal value of $1.26 currently owns 51.8% of Gland, having pared its stake over the years. Market capitalisation has shot up to Rs 32,964.47 crore with the Gland Pharma stock appreciating 10% in the year to date in anticipation of a transaction. It closed Friday at Rs 2,000. In the past month alone, it has shot up 16%. The Fosun stake alone would require a payout of Rs 17,141.28 crore ($1.9 billion).Change of control will involve an open offer for an additional 26% of the company from minority shareholders, making it a much larger transaction. If the open offer is fully subscribed, it would translate to a Rs 25,711 crore ($3 billion) acquisition at current and Gland didn't respond to queries. Brookfield and EQT declined to investors are of the view the stock is overpriced and are interested only at a discount to the current level. 'There are macro headwinds because of industry glut and geopolitics,' said one of the people cited. 'Fosun has to decide if it is okay to sell at a significantly lower price.'This factor could be a deal breaker, analysts said. 'At this level, the process looks tough,' said another industry official. Fosun at various times in recent years, renewed its search for a strategic or financial deal for Gland Pharma. The company ran a full sale process last year but aborted it, only to revive plans earlier this summer, mandating Morgan Stanley and UBS. Mint was first to report that PE interest in Gland had revived in in 1978 by PVN Raju, Gland Pharma develops and manufactures generic injectables for use in nearly 90 countries on five continents, with a focus on the Indian and US markets. As with other Chinese companies, Fosun has faced regulatory issues in India due to the frosty relationship between the two countries. Even its entry into India faced significant delays with deal contours needing tweaks to comply with FDI norms. Some experts said Fosun sees the timing as ideal for an exit. But with no success for years, Fosun has been selling down its shares in the public markets through block deals. Last year, it sold about 6% for ₹1,750 crore. 'The incremental growth for the company's base business in the US is likely to come at the cost of margins,' said Shyam Srinivasan of Goldman management is expecting Cenexi Group — a French injectables and CDMO company Gland acquired in 2023 — to break even by the December quarter. Gland has a toehold in Europe through Cenexi, but rebooting the organisation and its product mix has been analysts said Gland has a sound track record and its future prospects may attract buyers.A veteran industry expert said Gland Pharma has a 'strong compliance history' and its manufacturing quality is impeccable. Plus, a surge in demand is seen for large injectable capacities across the world, making it a good fit. Another strong push for Gland Pharma is the explosive growth in glucagon-like peptide-1(GLP-1) drugs for weight loss and diabetes. Novo Nordisk's Wegovy (semaglutide) is set to go off patent early next year in India and Canada, leading to a burst of generic variants expected to enter the market. This is likely to offset the current overcapacity of injectable assets around the world. Trade tensions between the US and China are adding to the interest in Indian contract manufacturing players for steady supplies. 'Although we have not seen any meaningful switching from China yet, such opportunities cannot be ruled out in the future,' an industry executive is also preparing for a larger play in the biologics business, focusing on expanding its biosimilar and biologic CDMO segment.'The company's collaboration with DRL (Dr Reddy's) and discussions with Henlius (of China) are progressing well, with revenue generation from DRL business expected from FY26,' it said in the presentation.
Time of India
an hour ago
- Time of India
Viceroy calls semiconductor unit of Vedanta a 'sham op'
Vedanta NEW DELHI: Continuing its tirade against mining heavyweight Anil Agarwal 's Vedanta group, US-based Viceroy Research has alleged that the group's semiconductor unit was a "sham commodities trading operation", designed to avoid classification as an NBFC, a charge the conglomerate called baseless. The short seller, which last week published a scathing report about Vedanta Group and followed it up with similar reports on group companies, in fresh allegations said Vedanta Ltd's subsidiary, Vedanta Semiconductors Pvt Ltd, was part of a scheme to allow the Mumbai-listed firm to remit brand fees to parent Vedanta Resources in April this year, when it faced a severe liquidity crisis. In a statement, Vedanta spokesperson said the group "strongly rejects the baseless allegations made in the report regarding Vedanta Semiconductors Pvt Ltd (VSPL)". "All business activities of VSPL have been transparently disclosed and are in line with statutory norms," it said. Viceroy said, "VSPL is a sham commodities trading operation designed to improperly avoid classification as a Non-Banking Financial Company (NBFC)". "This scheme was devised to facilitate Vedanta Ltd's remittance of brand fees to Vedanta Resources' (VRL) in April 2025, when it faced a severe liquidity crisis," Viceroy said. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo "VSPL's operational illusion needs 24 months of regulatory silence to fulfil its purpose, repaying its offshore lenders and hiding the near-catastrophe of April 2024. While credit analysts are snoozing through the alarm bells, India's regulators are famously light sleepers," it added. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
